These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 28747358)

  • 1. Urinary renin-angiotensin markers in polycystic kidney disease.
    Salih M; Bovée DM; Roksnoer LCW; Casteleijn NF; Bakker SJL; Gansevoort RT; Zietse R; Danser AHJ; Hoorn EJ
    Am J Physiol Renal Physiol; 2017 Oct; 313(4):F874-F881. PubMed ID: 28747358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.
    Park HC; Kang AY; Jang JY; Kim H; Han M; Oh KH; Kim SH; Noh JW; Cheong HI; Hwang YH; Ahn C
    BMC Nephrol; 2015 Jun; 16():86. PubMed ID: 26092580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
    Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
    J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney.
    van den Heuvel M; Batenburg WW; Jainandunsing S; Garrelds IM; van Gool JM; Feelders RA; van den Meiracker AH; Danser AH
    J Hypertens; 2011 Nov; 29(11):2147-55. PubMed ID: 21941204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary Angiotensinogen and Renin Excretion are Associated with Chronic Kidney Disease.
    Juretzko A; Steinbach A; Hannemann A; Endlich K; Endlich N; Friedrich N; Lendeckel U; Stracke S; Rettig R
    Kidney Blood Press Res; 2017; 42(1):145-155. PubMed ID: 28395289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A link between the intrarenal renin angiotensin system and hypertension in autosomal dominant polycystic kidney disease.
    Kocyigit I; Yilmaz MI; Unal A; Ozturk F; Eroglu E; Yazici C; Orscelik O; Sipahioglu MH; Tokgoz B; Oymak O
    Am J Nephrol; 2013; 38(3):218-25. PubMed ID: 23988725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?
    Persson F; Lu X; Rossing P; Garrelds IM; Danser AH; Parving HH
    J Hypertens; 2013 Aug; 31(8):1646-52. PubMed ID: 23743807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary angiotensinogen, related factors and clinical implications in normotensive autosomal dominant polycystic kidney disease patients.
    Kurultak I; Sengul S; Kocak S; Erdogmus S; Calayoglu R; Mescigil P; Keven K; Erturk S; Erbay B; Duman N
    Ren Fail; 2014 Jun; 36(5):717-21. PubMed ID: 24625116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease.
    Tiryaki Ö; Usalan C; Sayiner ZA
    Ren Fail; 2016; 38(2):222-7. PubMed ID: 26707134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
    Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
    BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary angiotensinogen as a potential biomarker of intrarenal renin-angiotensin system activity in Chinese chronic kidney disease patients.
    Xu Z; Xu B; Xu C
    Ir J Med Sci; 2015 Jun; 184(2):297-304. PubMed ID: 24664631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interrelationship between renin-angiotensin-aldosterone system and oxidative stress in chronic heart failure patients with or without renal impairment.
    Reina-Couto M; Afonso J; Carvalho J; Morgado L; Ronchi FA; de Oliveira Leite AP; Dias CC; Casarini DE; Bettencourt P; Albino-Teixeira A; Morato M; Sousa T
    Biomed Pharmacother; 2021 Jan; 133():110938. PubMed ID: 33171402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary angiotensinogen level is associated with potassium homeostasis and clinical outcome in patients with polycystic kidney disease: a prospective cohort study.
    Kim H; Park S; Jhee JH; Yun HR; Park JT; Han SH; Lee J; Kim SW; Kim YH; Oh YK; Kang SW; Choi KH; Yoo TH;
    BMC Nephrol; 2019 Mar; 20(1):104. PubMed ID: 30909873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ELISA examining urinary angiotensinogen as a potential indicator of intrarenal renin-angiotensin system (RAS) activity: a clinical study of 128 chronic kidney disease patients.
    Zhang XY; Ding XQ; Lv WL; Teng J; Zhong YH
    Mol Biol Rep; 2013 Oct; 40(10):5817-24. PubMed ID: 24065527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease.
    Mills KT; Kobori H; Hamm LL; Alper AB; Khan IE; Rahman M; Navar LG; Liu Y; Browne GM; Batuman V; He J; Chen J
    Nephrol Dial Transplant; 2012 Aug; 27(8):3176-81. PubMed ID: 22399491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronotherapy with a Renin-angiotensin System Inhibitor Ameliorates Renal Damage by Suppressing Intrarenal Renin-angiotensin System Activation.
    Aoki T; Ohashi N; Isobe S; Ishigaki S; Matsuyama T; Sato T; Fujikura T; Kato A; Miyajima H; Yasuda H
    Intern Med; 2020; 59(18):2237-2244. PubMed ID: 32938851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
    Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
    Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin blockade in late autosomal dominant polycystic kidney disease.
    Torres VE; Abebe KZ; Chapman AB; Schrier RW; Braun WE; Steinman TI; Winklhofer FT; Brosnahan G; Czarnecki PG; Hogan MC; Miskulin DC; Rahbari-Oskoui FF; Grantham JJ; Harris PC; Flessner MF; Moore CG; Perrone RD;
    N Engl J Med; 2014 Dec; 371(24):2267-76. PubMed ID: 25399731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.
    Torres VE; Abebe KZ; Schrier RW; Perrone RD; Chapman AB; Yu AS; Braun WE; Steinman TI; Brosnahan G; Hogan MC; Rahbari FF; Grantham JJ; Bae KT; Moore CG; Flessner MF
    Kidney Int; 2017 Feb; 91(2):493-500. PubMed ID: 27993381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of rapid disease progression in autosomal dominant polycystic kidney disease.
    Corradi V; Gastaldon F; Caprara C; Giuliani A; Martino F; Ferrari F; Ronco C
    Minerva Med; 2017 Feb; 108(1):43-56. PubMed ID: 27701376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.